Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Der Nettoumsatz wächst im dritten Quartal um 4% (+5% kWk)[1] - bei einer Steigerung der operativen Marge im dritten Quartal und in den ersten neun Monaten Der Nettoumsatz steigt im dritten Quartal...
-
Hausse de 4% (+5% tcc)[1] du chiffre d'affaires net au troisième trimestre (T3), avec une augmentation de la marge opérationnelle au T3 et sur les neuf premiers mois (M9) de 2014 Chiffre d'affaires...
-
Net sales up 4% (+5% cc)[1] in Q3, with operating margin increase across Q3 and 9M Net sales of USD 14.7 billion grew 4% (+5% cc[2]) in Q3 Strong operating income growth in Q3 of 14% (+18% cc)...
-
CSL to acquire Novartis influenza vaccines business, including development pipeline, for USD 275 million Announcement follows a transaction announced on April 22, 2014 to divest the...
-
Secukinumab is the first selective IL-17A inhibitor to meet primary endpoint in two pivotal Phase III studies showing improvement in active ankylosing spondylitis (AS) patients' symptoms versus...
-
Biologics License Application (BLA) for secukinumab, a "first-in-class" IL-17A inhibitor, is currently under FDA review with an anticipated action date in early 2015 FDA Advisory Committee...
-
Preliminary study results show 27 of 30 pediatric and adult patients with relapsed/refractory (r/r) ALL (90%) experienced complete remissions with personalized cell therapy, CTL019[1] Largest...
-
New analyses of Phase III data show consistent efficacy in clearing psoriasis skin with AIN457 (secukinumab) regardless of how bad patients' disease is at start of treatment[1] Significant...
-
Annual economic impact equals more than 350,000 healthy life years lost and over €20 billion EUR as a result of blindness for 14 countries studied Screening for diabetic retinopathy, cataracts...
-
Three members of the Executive Committee of Novartis to leave company, following completion of portfolio transactions expected to close in first half 2015 Basel, October 8, 2014 - Novartis...